Application of Houttuynoid C for preparing medicine for treating rhinitis

A technology for medicine and rhinitis, which is applied in the application field of Houttuynoid C in the preparation of medicine for treating rhinitis, and can solve the problems of ineffectiveness and poor curative effect of rhinitis.

Inactive Publication Date: 2013-03-27
何晓涛
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used in the treatment of rhinitis. These drugs have poor or ineffective effects on chronicity and recurrent rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Houttuynoid C for preparing medicine for treating rhinitis
  • Application of Houttuynoid C for preparing medicine for treating rhinitis
  • Application of Houttuynoid C for preparing medicine for treating rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1: the preparation of compound Houttuynoid C tablet involved in the present invention:

[0012] Take 20 grams of compound Houttuynoid C, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0013] Embodiment 2: the preparation of compound Houttuynoid C capsule of the present invention:

[0014] Get 20 grams of compound Houttuynoid C, add conventional auxiliary materials for preparing capsules such as 180 grams of starch, mix well, and pack into capsules to make 1000 tablets.

[0015] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0016] Experimental example 1, the influence of Houttuynoid C of the present invention on ovalbumin-induced allergic rhinitis in rats

[0017] Male SD rats, weighing 180-220 g, were intraperitoneally injected with 1 mg of ovalbumin and 10 mg of aluminum hydroxide gel, and then injected once every other day, a total of 7 times. From the 14th day, 10ul of 1mg / ml ovalbumin physiological saline solution was instilled into the nasal cavities of both sides of the rat every day, 7 times in total. Immediately after the last infusion, observe the number of times the rats sneeze and wipe their noses within 30 minutes, and the test drug is orally administered 1 hour before the last infusion of ovalbumin.

[0018] It can be seen from Table 1 that Houttuynoid C (10, 20mg / kg) significantly inhibited the sneezing and scratching nasal reactions in rats with allergic rhinitis induced by ovalbumin. Terfenadine 10mg / kg also showed a significant inhibitory effect.

[0019] Table 1 The effect of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to Houttuynoid C for treating immunity inflammation, which is used for preparing a medicine for treating immunity inflammation, in particular for preparing a medicine for treating rhinitis. Houttuynoid C has definite curative effect by using terfenadine and diclofenac sodium as contrasts. The application of Houttuynoid C for preparing the medicine for treating rhinitis is disclosed for the first time; because the skeleton type belongs to a brand new skeleton type and the rhinitis curative activity of Houttuynoid C is strong unexpectedly, the possibility that other compounds give any inspiration does not exist; Houttuynoid C has outstanding substantive characteristics; and simultaneously, Houttuynoid C has obvious progress for preventing and treating rhinitis.

Description

technical field [0001] The invention relates to the application of Houttuynoid C in the preparation of medicine for treating rhinitis. Background technique [0002] Rhinitis is a common and frequently-occurring disease in clinical practice. The occurrence of rhinitis is mainly related to allergic reactions and belongs to the category of immune inflammation. At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used for the treatment of rhinitis, and these drugs have poor or ineffective effects on chronicity and recurrent rhinitis. Therefore, small molecular compounds with clear components, quality control, safety and high efficiency have potential value in the development of drugs for rhinitis treatment. [0003] The compound Houttuynoid C involved in the present invention is a compound published in 2012 (Cai, J. Y. et al., 2012. Houttuynoid C, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P11/02
Inventor 何晓涛
Owner 何晓涛
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap